We are developing our VB-600 platform of biologic agents targeting MOSPD2 for oncology and inflammatory indications.

MOSPD2 is a membrane protein whose function was unknown. We discovered new biology findings in the regulation of cell motility, in which MOSPD2 seems to be playing a key role.  Our data indicate that MOSPD2 is required for directional movement, or chemotaxis, of tumor cells and certain immune cells, and therefore we believe it has a central role in both oncology and inflammation.